drugset / Trial / NCT01037842

Summary

We performed a prospective, randomized, multicenter trial to assess the efficacy and safety of combined treatment with mitiglinide and metformin for patients with type 2 diabetes who show inadequate glycemic control with metformin monotherapy. Subjects with HbA1c \>7.0% after an 8-week metformin run-in phase were randomized to a 16-week trial phase with metformin plus mitiglinide (Met+Mit) or metformin plus placebo (Met).

Timeline

Start
2006-08
Primary completion
2008-03
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mitiglinide Small molecule 10 mg